Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy.
Invasive aspergillosis is an important factor in the morbidity and mortality of patients suffering from hematologic disorders treated with chemotherapy. Treatment with amphotericin B is often limited because of toxicity, particularly nephrotoxicity. We describe a case of invasive pulmonary Aspergillus fumigatus infection in acute myeloid leukemia with renal failure due to amphotericin B therapy, which responded to treatment with a new antifungal agent, micafungin. Micafungin appears to be an effective and safe therapy for Aspergillus infections with renal failure due to amphotericin B.
Yokote
T
T
Department of First Internal Medicine, Osaka Medical College, 2-39-7 Daigakumachi, Takatsuki City, Osaka, Japan. in1161@poh.osaka-med.ac.jp
Akioka
T
T
Oka
S
S
Fujisaka
T
T
Yamano
T
T
Hara
S
S
Tsuji
M
M
Hanafusa
T
T
D000666:Amphotericin B / Q000009:adverse effects*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D054714:Echinocandins; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000382:microbiology*; D055666:Lipopeptides; D008074:Lipoproteins / Q000627:therapeutic use*; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D000077551:Micafungin; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000382:microbiology; D016896:Treatment Outcome
D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D000666:Amphotericin B; D000077551:Micafungin